About the Authors
- Pierrick Bedouch
-
Affiliation Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada
- Carlo A. Marra
-
Affiliation Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada
- J. Mark FitzGerald
-
Affiliations Center for Clinical Epidemiology and Evaluation, Vancouver Coastal Health Institute, Vancouver, British Columbia, Canada, Division of Respiratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
- Larry D. Lynd
-
* E-mail: larry.lynd@ubc.ca
Affiliation Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada
- Mohsen Sadatsafavi
-
Affiliations Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada, Center for Clinical Epidemiology and Evaluation, Vancouver Coastal Health Institute, Vancouver, British Columbia, Canada, Division of Respiratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
Competing Interests
The content of this article is the sole responsibility of the authors. Dr. FitzGerald has served on advisory boards for GlaxoSmithKline, AstraZeneca, Novartis, Pfizer, Boehringer-Ingelheim, Altana, Merck and Topigen. He has also been a member of speakers’ bureaus for Glaxo-SmithKline, AstraZeneca, Boehringer-Ingelheim, Pfizer and Merck. He has received research funding paid directly to the University of British Columbia from the Canadian Institutes of Health Research, AstraZeneca, Glaxo-SmithKline, Boehringer-Ingelheim, Merck, Wyeth, Schering, Genentech and Topigen. Dr. FitzGerald is a member of the Global Initiative for Asthma (GINA) and is chair of the GINA Science Committee. Dr. Bedouch has received financial support for research activities from drug companies including Actelion, Bioprojet, Glaxo-SmithKline. He has had access to unrestricted grants from Sanofi-Aventis France and the Grenoble University Hospital, France. He has also received fees from Actelion for participation in scientific advisory board. Dr. Sadatsafavi was funded by a Canadian Institutes of Health Research fellowship award. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: PB MS JMF CM LL. Performed the experiments: PB MS. Analyzed the data: MS. Contributed reagents/materials/analysis tools: LL CM. Wrote the paper: PB MS.